ArticlePloS one2013
Urinary fetuin-A is a novel marker for diabetic nephropathy in type 2 diabetes identified by lectin microarray.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 61 citations in OpenAlex.
- Association of urinary post-translationally modified fetuin-a and outcomes in acute kidney disease.BMC nephrology · 2026Article
- Article
- Glycosylation in kidney diseases.Precision clinical medicine · 2025Review
- Urinary Fetuin-A with Specific Post-Translational Modification in Type 1 Diabetes Patients with Normoalbuminuria and Preserved Kidney Function.Diagnostics (Basel, Switzerland) · 2025Article
- Augmented Intrarenal and Urinary Angiotensinogen in Diabetic Nephropathy: The Role of Isoflavones.International journal of molecular sciences · 2025Review
- The evolving roles of fetuin-A in type 2 diabetes mellitus and its potential clinical implications: a review.Therapeutic advances in chronic disease · 2025Review
- Insights into the Novel Biomarkers Expressed in Diabetic Nephropathy: Potential Clinical Applications.Current pharmaceutical design · 2025Review
- Deciphering disease through glycan codes: leveraging lectin microarrays for clinical insights.Acta biochimica et biophysica Sinica · 2024Review
- Associations of urinary fetuin-A with histopathology and kidney events in biopsy-proven kidney disease.Clinical kidney journal · 2024Article
- Urinary Post-Translationally Modified Fetuin-A (uPTM-FetA) in Chronic Kidney Disease Patients with and without Diabetic Kidney Disease.Medicina (Kaunas, Lithuania) · 2024Article
- External Validation of a Urinary Biomarker Risk Score for the Prediction of Steroid Responsiveness in Adults With Nephrotic Syndrome.Kidney international reports · 2023Article
- Glycans in spent embryo culture medium are related to the implantation ability of blastocysts.Heliyon · 2023Article
- Role of Fetuin-A in the Pathogenesis of Psoriasis and Its Potential Clinical Applications.Clinical, cosmetic and investigational dermatology · 2022Review
- Proteomic Analysis of Aqueous Humor Proteins in Association with Cataract Risks: Diabetes and Smoking.Journal of clinical medicine · 2021Article
- Comprehensive analysis of glycosphingolipid glycans by lectin microarrays and MALDI-TOF mass spectrometry.Nature protocols · 2021Article
- Nanoproteomic Approach for Isolation and Identification of Potential Biomarkers in Human Urine from Adults with Normal Weight, Overweight and Obesity.Molecules (Basel, Switzerland) · 2021Article
- Diabetic retinopathy in the Eastern Morocco: Different stage frequencies and associated risk factors.Saudi journal of biological sciences · 2021Article
- Novel Urinary Glycan Biomarkers Predict Cardiovascular Events in Patients With Type 2 Diabetes: A Multicenter Prospective Study With 5-Year Follow Up (U-CARE Study 2).Frontiers in cardiovascular medicine · 2021Article
- Application of Lectin Microarrays for Biomarker Discovery.ChemistryOpen · 2020Review
- IgA regulates the composition and metabolic function of gut microbiota by promoting symbiosis between bacteria.The Journal of experimental medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We analyzed the urine samples of patients with type 2 diabetes at various stages of diabetic nephropathy by lectin microarray to identify a biomarker to predict the progression of diabetic nephropathy. Japanese patients with type 2 diabetes at various stages of nephropathy were enrolled and we performed lectin microarray analyses (n = 17) and measured urinary excretion of fetuin-A (n = 85). The increased signals of urine samples were observed in Siaα2-6Gal/GalNAc-binding lectins (SNA, SSA, TJA-I) during the progression of diabetic nephropathy. We next isolated sialylated glycoproteins by using SSA-lectin affinity chromatography and identified fetuin-A by liquid chromatography-tandem mass spectrometer. Urinary excretion of fetuin-A significantly increased during the progression of albuminuria (A1, 0.40 ± 0.43; A2, 0.60 ± 0.53; A3 1.57 ± 1.13 ng/gCr; p = 7.29 × 10(-8)) and of GFR stages (G1, 0.39 ± 0.39; G2, 0.49 ± 0.45; G3, 1.25 ± 1.18; G4, 1.34 ± 0.80 ng/gCr; p = 3.89 × 10(-4)). Multivariate logistic regression analysis was employed to assess fetuin-A as a risk for diabetic nephropathy with microalbuminuria or GFR<60 mL/min. Fetuin-A is demonstrated as a risk factor for both microalbuminuria and reduction of GFR in diabetic nephropathy with the odds ratio of 4.721 (1.881-11.844) and 3.739 (1.785-7.841), respectively. Collectively, the glycan profiling analysis is useful method to identify the urine biomarkers and fetuin-A is a candidate to predict the progression of diabetic nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.